BR112023023260A2 - Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica - Google Patents

Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica

Info

Publication number
BR112023023260A2
BR112023023260A2 BR112023023260A BR112023023260A BR112023023260A2 BR 112023023260 A2 BR112023023260 A2 BR 112023023260A2 BR 112023023260 A BR112023023260 A BR 112023023260A BR 112023023260 A BR112023023260 A BR 112023023260A BR 112023023260 A2 BR112023023260 A2 BR 112023023260A2
Authority
BR
Brazil
Prior art keywords
vector
disease
treating
subject
producing
Prior art date
Application number
BR112023023260A
Other languages
English (en)
Inventor
Brunsvik Fredriksen Agnete
Trygge Haugen Bersaas Audun
Pierre Dillard
Stine Granum
Original Assignee
Nykode Therapeutics ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nykode Therapeutics ASA filed Critical Nykode Therapeutics ASA
Publication of BR112023023260A2 publication Critical patent/BR112023023260A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica. a presente invenção refere-se aos vetores, tais como plasmídeos de dna, compreendendo sequências múltiplas de ácido nucleico engenheiradas para serem coexpressas como moléculas separadas. tais moléculas separadas incluem um primeiro polipeptídeo, em que o primeiro polipeptídeo compreende uma unidade de alvejamento que alveja células que apresentam antígeno, uma unidade de multimerização, tal como unidade de dimerização e uma unidade antigênica compreendendo um ou mais antígenos ou partes dos mesmos e um ou mais compostos imunoestimulatórios.
BR112023023260A 2021-05-10 2022-05-10 Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica BR112023023260A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA202170221 2021-05-10
DKPA202170364 2021-07-08
DKPA202270113 2022-03-18
DKPA202270186 2022-04-07
PCT/EP2022/062665 WO2022238420A2 (en) 2021-05-10 2022-05-10 Co-expression of constructs and immunostimulatory compounds

Publications (1)

Publication Number Publication Date
BR112023023260A2 true BR112023023260A2 (pt) 2024-01-30

Family

ID=82016537

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023260A BR112023023260A2 (pt) 2021-05-10 2022-05-10 Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica

Country Status (8)

Country Link
EP (1) EP4337248A2 (pt)
JP (1) JP2024516882A (pt)
KR (1) KR20240019135A (pt)
AU (1) AU2022274154A1 (pt)
BR (1) BR112023023260A2 (pt)
CA (1) CA3216720A1 (pt)
IL (1) IL308310A (pt)
WO (1) WO2022238420A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932603B2 (en) 2003-02-25 2015-01-13 Vaccibody As Modified antibody
WO2011161244A1 (en) 2010-06-25 2011-12-29 Vaccibody As Homodimeric protein constructs
AU2012356969B2 (en) 2011-12-21 2017-05-04 Nykode Therapeutics ASA Vaccines against HPV
EP3362103A4 (en) * 2015-10-12 2020-02-05 Nantomics, LLC COMPOSITIONS AND METHODS USING VIRAL CANCER NEOEPITOPES
KR20180100659A (ko) 2016-01-08 2018-09-11 백시바디 에이에스 치료적 항암 네오에피토프 백신
BR112021005702A8 (pt) 2018-09-27 2022-11-08 Vaccibody As Método para selecionar neoepítopos
CN113631185A (zh) 2019-02-27 2021-11-09 尼克塔治疗公司 用于治疗癌症的免疫治疗组合
WO2020221783A1 (en) 2019-04-29 2020-11-05 Vaccibody As Methods for pre-selection of neoepitopes
KR20230004585A (ko) 2020-04-09 2023-01-06 니코데 테라퓨틱스 에이에스에이 개별화된 치료용 항암 백신
JP2023524054A (ja) 2020-05-01 2023-06-08 ナイコード セラピューティクス アルメン アクスイェ セルスカプ ベータコロナウイルスの予防と治療
EP4181949A1 (en) 2020-07-14 2023-05-24 Evaxion Biotech A/S Apc targeting units for immunotherapy

Also Published As

Publication number Publication date
EP4337248A2 (en) 2024-03-20
IL308310A (en) 2024-01-01
AU2022274154A1 (en) 2023-11-16
CA3216720A1 (en) 2022-11-17
KR20240019135A (ko) 2024-02-14
WO2022238420A3 (en) 2022-12-22
WO2022238420A2 (en) 2022-11-17
JP2024516882A (ja) 2024-04-17

Similar Documents

Publication Publication Date Title
EA201991440A1 (ru) ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
EA201892810A1 (ru) Гибридные последовательности нуклеиновых кислот для геномной инженерии
BR112018076259A2 (pt) tagmentação usando transposomas imobilizados com ligantes
AU2018298422A1 (en) Novel nucleic acid molecules
BR112015023424A2 (pt) construto de expressão engenheirado, método para aprimoramento de produção de rna ou proteína, vetor, célula, hospedeira bacteriana, sistema de cultura de célula para síntese in vivo de dsrna, composição e método para controlar uma infestação de pragas de invertebrados ou para inibir a propagação de uma doença viral em uma população de plantas, e terminador transcricional
BR112017016681A2 (pt) vetor de coexpressão de vacina e moléculas coestimulatórias
MX2018011384A (es) Arn de replicacion en trans.
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
BR112017026719A8 (pt) Nucleases cas9 termostáveis
BR112018010635A2 (pt) linhagens celulares estáveis para a produção retroviral
BR112015012375A2 (pt) modificação e regulação de genoma à base de crispr
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
Kalliomaa-Sanford et al. Chromosome segregation in Archaea mediated by a hybrid DNA partition machine
BR112022021459A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
BR112023023260A2 (pt) Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica
WO2015009678A3 (en) Specific targeting of rna expanded repeat sequences
WO2016130628A8 (en) Griffithsin mutants
Mairhofer et al. Advances in host and vector development for the production of plasmid DNA vaccines
BR112021023899A2 (pt) Método para o tratamento da distrofia muscular por direcionamento ao gene da dmpk
Aditham et al. Chemically modified mocRNAs for highly efficient protein expression in mammalian cells
Janowski et al. The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize
AR102803A1 (es) Vacunas de reovirus aviar
AR102762A1 (es) Secuencia de oligonucleótidos para uso en ingeniería de rutas metabólicas